Roche has unveiled a transformative USD 50 billion investment plan in the United States over the next five years, aimed at significantly expanding its pharmaceutical and diagnostics operations while reinforcing its already robust presence of over 25,000 employees across 24 sites. This commitment includes the development of state-of-the-art R&D centers and the expansion of manufacturing facilities in Indiana, Pennsylvania, Massachusetts, California, and a forthcoming location. The investment is expected to generate more than 12,000 new jobs, including 1,000 positions within Roche and over 11,000 construction and support roles linked to new manufacturing capabilities.
Also Read: eBay partners with Checkout.com for global payments
The initiative will bolster Roche’s U.S. infrastructure with upgraded distribution centers for its innovative medicines and diagnostics in states like Kentucky, New Jersey, and Oregon. Key projects include a gene therapy manufacturing facility in Pennsylvania, a 900,000 square foot site dedicated to next-generation weight loss treatments, a new continuous glucose monitoring facility in Indiana, and a cutting-edge R&D hub in Massachusetts focused on AI and research in cardiovascular, renal, and metabolic diseases. According to Roche, these strategic investments aim to elevate the company’s innovation engine while enhancing access to life-changing therapies across the U.S. and beyond.